21:51 , Dec 6, 2018 |  BC Innovations  |  Emerging Company Profile

Novintum: bugging cancer

Springing off the endosymbiotic theory, which holds that mitochondria evolved from primitive bacteria, Novintum Bioscience Ltd. is targeting mitochondrial metabolism with antibiotics to treat relapsed or treatment-resistant cancers. CEO Tim Sparey said Novintum’s strategy arose...
20:33 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
01:15 , Jan 12, 2018 |  BC Innovations  |  Product R&D

Avidity’s affinity for muscle

Avidity Biosciences LLC has developed a strategy for delivering siRNA and antisense therapies to tissues outside the liver and has preclinical proof-of-concept for two molecules that target muscle. The company has set its next sights...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:43 , Dec 1, 2017 |  BC Week In Review  |  Company News

Neuropathic pain company Quartet ending operations

In a blog post, former Chairman of Quartet Medicine Inc. (Cambridge, Mass.) Bruce Booth said the biotech is winding down its operations. According to the post, Quartet found "some concerning and unexpected neurologic effects in...
21:47 , Nov 30, 2017 |  BC Innovations  |  Targets & Mechanisms

All-purpose HSCs

While most eyes are on hematopoietic stem cells for their ability to treat blood cancers, a UCSD group has built a body of work showing the immune cell precursors can treat diseases with no relation...
23:42 , Nov 17, 2017 |  BC Extra  |  Company News

Neuropathic pain company Quartet ending operations

In a blog post, former Chairman of Quartet Medicine Inc. (Cambridge, Mass.) Bruce Booth said the biotech is winding down its operations. According to the post, Quartet found "some concerning and unexpected neurologic effects in...
19:50 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pneumococcus Rabbit studies suggest a vaccine based on an S. pneumoniae CPS mimic could help prevent invasive pneumococcal disease caused by the pathogen's serotype 5. The vaccine consisted of a synthetic oligosaccharide mimic of...
23:22 , Oct 24, 2017 |  BC Extra  |  Politics & Policy

CFDA proposes changes to Drug Administration Act

China FDA proposed amendments to the country's Drug Administration Act that it hopes will encourage innovation while shortening drug approval timelines. The proposals include full implementation of the Marketing Authorization Holder (MAH) system, which allows...